Join Us At ELRIG Drug Discovery 2024!

Join us at ELRIG Drug Discovery 2024 from Oct 2-3 in London! Visit us at booth C23 and don’t miss our poster, presented by AI-enabled Drug Discovery company, Evariste, exemplifying a perfect case study of how EditCo Bio's high-throughput cell engineering platform is opening new doors in drug target identification and validation. 

Poster Key Takeaways: 

• Synthetic lethality (SL) is a highly promising therapeutic strategy in oncology, but the toolbox of existing actionable SL gene pairs remains limited. 
• Using an AI-driven pipeline, Evariste have identified novel SL gene pairs and validated them through a combination of high-throughput CRISPR editing and robotically-enabled cell biology assays.
• Further validation was performed for a novel SL pair where the druggable gene is the known oncology target FAK, demonstrating that this pipeline robustly identifies clinically actionable targets with well-defined patient populations.